Clinical trial
Usefulness of Angiomammography for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT05402930 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Usefulness of Angiomammography for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer
- Lead sponsor
- CHU de Quebec-Universite Laval
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 3, 2018
- Completion date
- December 31, 2025
- Enrollment
- 67 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.